<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5970">
  <stage>Registered</stage>
  <submitdate>27/04/2015</submitdate>
  <approvaldate>27/04/2015</approvaldate>
  <nctid>NCT02447081</nctid>
  <trial_identification>
    <studytitle>AmplatzerAmulet Post-Market Study</studytitle>
    <scientifictitle>AmplatzerAmulet Observational Post-Market Study</scientifictitle>
    <utrn />
    <trialacronym>Amuletâ„¢PMS</trialacronym>
    <secondaryid>SJM-CIP-10053</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <healthcondition>Thromboembolism</healthcondition>
    <healthcondition>Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Subjects implanted with Amulet Device

Subjects implanted with Amulet Device - All subjects who receive the Amulet device will be followed.


Treatment: devices: Subjects implanted with Amulet Device
Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assessment of acute serious adverse events</outcome>
      <timepoint>0 to 7 days post procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assessment of late serious adverse events greater than 7 days post procedure</outcome>
      <timepoint>Greater than 7 days through 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Report the composite percentage of stroke (ischemic), systemic embolism and cardiovascular death</outcome>
      <timepoint>implant through 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Report the percentage of bleeding events</outcome>
      <timepoint>Implant through 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Technical success - Was Amulet device implanted</outcome>
      <timepoint>Implant procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural success - Procedural success is based on Amulet device being implanted day 0 through hospital discharge, on average one night stay (day 1). Was Amulet device implanted and subject discharged the following day without an adverse event</outcome>
      <timepoint>Implant through hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oral anti-coagulation usage</outcome>
      <timepoint>through 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject with history of paroxysmal, persistent or permanent NVAF

          2. Subject who is 18 years or older, or of legal age to give informed consent specific to
             state and national law

          3. Subject who is eligible for an Amulet LAA Occluder device according to current
             international guidelines and per physician discretion

          4. Subject who is willing and capable of providing informed consent, participating in all
             associated study activities</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject with evidence of an intracardiac thrombus

          2. Subject with active infection or active endocarditis or other infections producing
             bacteremia

          3. Subject where the placement of the device would interfere with any intracardiac or
             intravascular structures

          4. Subject with any medical disorder that would interfere with completion or evaluation
             of clinical study results

          5. Women of childbearing potential who are, or plan to become, pregnant during the time
             of the study (method of assessment per physician discretion)

          6. Subject with LAA anatomy that does not accommodate a device per the sizing guidelines</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational [Patient Registry]</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1088</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>WA 6150 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Uusimaa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Aquitaine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Burgundy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>North-Calais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Picardy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hesse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine-Westphal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Thuringia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Segeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Quedlinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Winnenden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Caserta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Massa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Veenendaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalusia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Balearic Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castile and Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalonia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Extremadura</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northwest England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>South East England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This will be a prospective, multicenter, observational, non-randomized study to compile real
      world outcome data on the use of the Amuletdevice in non-valvular atrial fibrillation (NVAF)
      subjects. The study is designed to follow the Instructions For Use (IFU) to gather data on
      the implant procedure through two years of follow up with the Amulet device in a commercial
      clinical setting.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02447081</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Hildick-Smith, MD</name>
      <address>Brighton and Sussex University Hospitals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>